MapLight Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 16, 2026, reporting a net loss of $51.6 million for the three months ended September 30, 2026, and $172.5 million for the nine months ended September 30, 2026.
Key Highlights
- Third-quarter net loss: The company reported a net loss of $51,616 thousand for the three months ended September 30, 2026, compared to $29,418 thousand for the same period in 2025.
- Nine-month net loss: For the nine months ended September 30, 2026, the net loss totaled $172,476 thousand, versus $81,604 thousand in the prior-year period.
- Total operating expenses: Research and development expenses reached $151,328 thousand and general and administrative expenses reached $32,067 thousand for the nine months ended September 30, 2026.
- Cash and investments: As of September 30, 2026, the company held $55,568 thousand in cash and cash equivalents, $228,512 thousand in short-term investments, and $179,333 thousand in long-term investments.
- Accumulated deficit: The accumulated deficit stood at $532,996 thousand as of September 30, 2026, up from $360,520 thousand at December 31, 2025.
- Shares outstanding: As of November 11, 2026, the registrant had 56,207,896 total shares outstanding, comprising 53,480,385 shares of Voting Common Stock and 2,727,511 shares of Non-Voting Common Stock.
MapLight Therapeutics Reports Widening Losses as R&D Spending More Than Doubles
According to the filing, MapLight Therapeutics, Inc. (NASDAQ:MPLT), a Delaware-incorporated clinical-stage company headquartered in Redwood City, California, reported a significant increase in operating expenses for both the three and nine months ended September 30, 2026. Research and development expenses for the third quarter of 2026 were $44,208 thousand, compared to $27,094 thousand in the third quarter of 2025. For the nine-month period, R&D expenses grew to $151,328 thousand from $73,726 thousand in the comparable prior-year period, according to the filing.
General and administrative expenses also increased materially, the filing disclosed, rising to $11,135 thousand for Q3 2026 from $4,404 thousand in Q3 2025, and to $32,067 thousand from $11,980 thousand for the nine-month period. Total operating expenses for the nine months ended September 30, 2026 were reported as $183,395 thousand, compared to $85,706 thousand in the same period of 2025. The company reported interest income of $7,915 thousand and other income of $3,004 thousand for the nine months ended September 30, 2026, partially offsetting operating losses.
The condensed consolidated balance sheet as of September 30, 2026 showed total assets of $477,183 thousand and total liabilities of $31,412 thousand, resulting in total stockholders' equity of $445,771 thousand. Common shares issued and outstanding were 55,669,897 at September 30, 2026, up from 44,024,088 at December 31, 2025. The net loss per share on a basic and diluted basis was $(0.97) for Q3 2026 and $(3.60) for the nine months ended September 30, 2026, based on weighted-average shares outstanding of 53,100,322 and 47,964,806, respectively, the filing stated. The company identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
What Was Disclosed
MapLight Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing a nine-month net loss of $172,476 thousand, an accumulated deficit of $532,996 thousand, and combined cash, short-term, and long-term investment holdings of $463,413 thousand as of that date.




Please wait processing your request...